Investing.com -- Copenhagen-listed shares in Novo Nordisk (CSE:NOVOb) edged up by 3.8% on Thursday, touching a fresh record high. The Danish pharmaceutical giant has seen its share price surge by ...

Derek Saul has covered markets for the Forbes news team since 2021. Danish pharmaceutical giant Novo Nordisk reported the most robust quarterly profits and sales in its history Thursday ...

Both Novo and Lilly have struggled to keep up with demand for the drugs, which are in shortage. Novo Nordisk and Eli Lilly achieved the highest year-on-year (YoY) revenue growth when compared to ...

Eli Lilly's shares jumped to a record high following a better-than-expected earnings report, while ... More shares of Novo Nordisk skyrocketed on the heels of a promising clinical trial.

Sanders opened the hearing by displaying charts comparing Novo Nordisk's prices charged to ... about how insurance conglomerates are taking in record profits or how PBMs are being investigated ...

The stock is up 8.55% over the last year and 7.45% year-to-date. Let’s look at what the charts indicate for Novo Nordisk stock and how the stock maps against Wall Street estimates. Novo Nordisk ...

(Bloomberg) -- Novo Nordisk A/S’s shares fell by the most on record after a failed attempt to leapfrog rival Eli Lilly & Co. in the red-hot market for obesity drugs. Novo’s experimental ...

Wegovy sales continued to soar, recording DKK 17.4 billion in sales, representing a surge of 83%, driven by high prescription rates and Novo Nordisk’s efforts to meet the same. Year to date ...

(SOUNDBITE OF ARCHIVED RECORDING) BERNIE SANDERS: But you still have not answered my question - it's a very simple question - why Novo Nordisk is charging Americans substantially higher prices for ...